401 related articles for article (PubMed ID: 18668443)
1. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
2. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer.
Patil AG; D'Souza R; Dixit N; Damre A
Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):115-9. PubMed ID: 21725799
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
4. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
[TBL] [Abstract][Full Text] [Related]
5. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
6. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
7. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
8. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
9. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
11. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
12. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
13. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
[TBL] [Abstract][Full Text] [Related]
14. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
15. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
16. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
17. Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea.
Hellum BH; Tosse A; Hoybakk K; Thomsen M; Rohloff J; Georg Nilsen O
Planta Med; 2010 Mar; 76(4):331-8. PubMed ID: 19790032
[TBL] [Abstract][Full Text] [Related]
18. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.
Jain R; Majumdar S; Nashed Y; Pal D; Mitra AK
Mol Pharm; 2004; 1(4):290-9. PubMed ID: 15981588
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
20. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
